Major Relief for Pharmaceutical Companies: Court Exemption Granted for Minor Offences

Pharmaceutical companies will no longer be required to appear before courts for certain minor violations, according to reliable sources citing recently revised guidelines. In such cases, companies will be allowed to pay monetary penalties subject to specified conditions and undertake necessary self-corrective measures.

As part of efforts to ease business operations, several minor offences under the Drugs and Cosmetics Act, 1940 and other related laws have been decriminalised through the Jan Vishwas Act. Under this framework, the Drugs and Cosmetics (Compounding of Offences) Rules, 2025 have been introduced, bringing significant changes to the existing guidelines. The Act governs the safety, efficacy and quality of drugs, cosmetics and medical devices in the country and non-compliance may lead to regulatory action.

To reduce the burden on the judicial system and facilitate resolution of minor and technical violations, Section 32B has been introduced to enable compounding of offences. The Central Drugs Standard Control Organisation (CDSCO), operating under the Ministry of Health and Family Welfare, has framed the Drugs and Cosmetics (Compounding of Offences) Rules, 2025, outlining the new “compounding of offences” mechanism. However, the specific penalty amounts and the exact offences covered under these provisions have not yet been clearly specified.